// App-Quantinova.ai

1637 : Subcutaneous Rituximab in Combination with Fludarabine and Cyclophosphamide for Patients with CLL: Initial Results of a Phase Ib Study (SAWYER [BO25341]) Show Non-Inferior Pharmacokinetics and Comparable Safety to That of Intravenous Rituximab

Researchers

Presenter

  • Valeria Buccheri

Principal Investigators

  • Alain Delmer

  • Gottfried Doelken

  • Gianluca Gaidano

  • Christine McIntyre

  • Mike Brewster

  • Florence Hourcade-Potelleret

  • Pakeeza Sayyed

  • Xavier Badoux

Medical Centers

  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil

  • Hematology, University of Eastern Piedmont Amedeo Avogadro, Novara, Italy

  • Service -Hematologie Clinique, CHU de Rennes, Rennes, France

  • Klinik fuer Innere Medizin C und Poliklinik, University Greifswald, Greifswald, Germany

  • Department of Haematology, St George Hospital, Kogarah, Australia

  • Division of Hematology and Department of Oncology, Jewish General Hospital, Montreal, QC, Canada

Locations

  • Brazil

  • Canada

  • Italy

  • Germany

  • Australia

  • France

Companies

  • F. Hoffmann-La Roche

  • Feng Chi Biotech Cor

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Chronic Lymphocytic Leukemia

  • Neutropenia

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Rituximab

  • fludarabine tablet

  • Mofezolac

Outcome

  • N/A

Study Design

  • open label

  • fixed dose

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved